Goodwin Procter advised Arrakis Therapeutics on the deal.Arrakis Therapeutics announced its research collaboration agreement with Amgen (NASDAQ:AMGN), focused on the discovery and development of RNA degrader therapeutics…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
